H. Pylori Infection Clinical Trial
Official title:
A Prospective Cohort Study of Early Detection and Screening Strategy for Gatric Cancer in Sichuan Province China (SIGES-01)
To establish prospective cohort of healthy population and corresponding serum sample bank in Sichuan province to provide platform for exploring early diagnosis and screening strategy of gastric cancer by a prospective cohort study.
H. pylori was one of the most important carcinogenic factor for gastric cancer and play a
crucial role in inducing gastritis, atrophy and canceration. Chronic atrophic gastritis (CAG)
was a common precancerous disease, people with CAG become high-risk population and need
regular follow-up. However, study about occurrence risk prediction for gastric cancer when H.
pylori infection concurrence with CAG was still spare. In especial, there was still no
population screening program based on serology. The relative clinical epidemiology for
providing evidence for China gastric cancer screening program was very rare.
This study aim to evaluate gastric cancer occurrence risk and diagnostic value of people
combined with H. pylori infection and CAG by Serological methods in Sichuan province China.
We also project to design optimized screening program suitable for people in sichuan province
China.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT06045494 -
The Efficacy of Treatment for Helicobacter Pylori Infection in Preschooler by Yoghurt With LG21
|
N/A | |
| Not yet recruiting |
NCT01449500 -
Supplementation With L. Reuteri in H. Pylori Infected Adults
|
N/A | |
| Completed |
NCT01234389 -
Immediate Detection of Helicobacter Infection With a New Electrochemical System.
|
N/A | |
| Not yet recruiting |
NCT05387005 -
Screening Strategy for Gastric Cancer Prevention
|
N/A | |
| Not yet recruiting |
NCT02761005 -
Eradication of H. Pylori Therapy Individualized by the Mutation of 23S rRNA of H. Pylori
|
Phase 2 | |
| Recruiting |
NCT03142620 -
Effect of Vitamin D on Drug Resistant Helicobacter Pylori (HP) Eradication Study
|
Phase 3 | |
| Withdrawn |
NCT02090738 -
A Randomized, Open-label Study on Helicobacter Pylori Eradication With Standard Triple Regimen Plus Acetazolamide
|
Phase 2 | |
| Recruiting |
NCT01335334 -
H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study
|
Phase 4 | |
| Recruiting |
NCT05544396 -
Study on the Probiotics Regulating miRNA in H. Pylori-induced Wnt/β-catenin Gastric Carcinogenesis.
|
N/A | |
| Recruiting |
NCT04713670 -
Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection
|
Phase 4 | |
| Recruiting |
NCT06045832 -
Oral Helicobacter Pylori Eradication
|
N/A | |
| Completed |
NCT05453994 -
Bismuth for PCAB-based H. Pylori Eradication
|
||
| Recruiting |
NCT02328131 -
European Registry on the Management of Helicobacter Pylori Infection
|
||
| Completed |
NCT00197457 -
Pepsinogens as the Early Marker of H. Pylori Eradication
|
Phase 2 | |
| Completed |
NCT04036838 -
ARJ C13 Urea Breath Test System
|
Phase 2 | |
| Completed |
NCT06050824 -
A Comparative Study Between Concomitant Versus Load Therapy in Eradication of Helicobacter Pylori Infection
|
Phase 4 | |
| Completed |
NCT02767479 -
Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori
|
Phase 3 | |
| Completed |
NCT01505127 -
Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori
|
Phase 3 | |
| Recruiting |
NCT05176821 -
Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection
|
N/A | |
| Completed |
NCT05002595 -
H. Pylori Treatment Between Modified Quadruple Regimen and Tailored Therapy
|